By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Kadmon Corporation (Formerly Known As Kadmon Pharmaceuticals) 

Alexandria Center for Life Sciences
450 East 29th Street, 5th Floor
New York  New York  10016  U.S.A.
Phone: 212-308-6000 Fax: n/a




Company News
Kadmon To Present Preclinical Data Demonstrating That Its Novel Immuno-Oncology Compound Achieves Long-Lasting And Persistent Antitumor Immunity 4/15/2016 10:59:12 AM
Kadmon Announces Publication Of Data Demonstrating The Potential Of ROCK2 Inhibition To Treat Chronic Graft-Versus-Host Disease 3/22/2016 11:39:47 AM
Kadmon To Present Preclinical Data Demonstrating ROCK2 Signaling As A Key Regulator Of T Follicular Helper Cell Function In Autoimmune Conditions 2/26/2016 10:30:47 AM
Kadmon To Present Preclinical Data Demonstrating The Importance Of ROCK2 Signaling In Modulating Immune Response 1/12/2016 12:35:34 PM
Kadmon Initiates Phase 2 Clinical Trial Evaluating Tesevatinib In Non-Small Cell Lung Cancer With Activating EGFR Mutations And Brain Metastases Or Leptomeningeal Disease 12/18/2015 11:20:52 AM
Kadmon Announces Agreement With Jinghua Pharmaceutical Co. To Discover, Develop And Commercialize Antibody Product Candidates In China 11/23/2015 12:39:34 PM
Kadmon, Jinghua Pharma Forge $50 Million Antibody Deal 11/20/2015 7:03:20 AM
Kadmon Corporation Presents Preclinical Data On Immuno-Oncology Anti-PD-L1/IL-15 Fusion Protein At AACR-NCI-EORTC Symposium 11/4/2015 10:54:03 AM
Kadmon Corporation To Present Clinical Data On Tesevatinib For The Treatment Of Polycystic Kidney Disease At American Society of Nephrology's Kidney Week 2015 11/3/2015 12:50:11 PM
Kadmon Corporation To Present At The Rodman & Renshaw 17th Annual Global Investment Conference 9/4/2015 9:57:21 AM